Pasar al contenido principal

HETEROGENEIDAD CLINICA, GENETICA Y ALELICA DE LAS ENFERMEDADES RENALES HEREDITARIAS DE DEBUT TEMPRANO: NUEVAS CAUSAS MOLECULARES DE ANOMALIAS CONGENITAS DEL RIÑON Y EL TRACTO URINARIO

PI19/01633

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants

  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Martínez, Víctor
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Rius Peris, Asunción
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Berná, Gerson
  • Mazon, Jaime
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Gich, Ignasi|||0000-0003-3975-6588
  • Pérez, Hugo Vergara
  • Gomá-Garcés, Elena
  • Albero Dolon, José Luis
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Clinical variability among individuals with heterozygous pathogenic/likely pathogenic (P/LP) variants in the COL4A3 / COL4A4 genes (also called autosomal dominant Alport syndrome or COL4A3/COL4A4 -related disorder) is huge; many individuals are asymptomatic or show microhematuria, while others may develop proteinuria and chronic kidney disease (CKD). The prevalence of simple kidney cysts (KC) in the general population varies according to age, and patients with advanced CKD are prone to have them. A possible association between heterozygous COL4A3, COL4A4 and COL4A5 P/LP variants and KC has been described in small cohorts. The presence of KC in a multicenter cohort of individuals with heterozygous P/LP variants in the COL4A3 / COL4A4 genes is assessed in this study. We evaluated the presence of KC by ultrasound in 157 individuals with P/LP variants in COL4A3 (40.7%) or COL4A4 (53.5%) without kidney replacement therapy. The association between presence of KC and age, proteinuria, estimated glomerular filtration rate (eGFR) and causative gene was analyzed. Prevalence of KC was compared with historical case series in the general population. Half of the individuals with P/LP variants in COL4A3 / COL4A4 showed KC, which is a significantly higher percentage than in the general population. Only 3.8% (6/157) had cystic nephromegaly. Age and eGFR showed an association with the presence of KC (P <.001). No association was found between KC and proteinuria, sex or causative gene. Individuals with COL4A3 / COL4A4 P/LP variants are prone to develop KC more frequently than the general population, and their presence is related to age and to eGFR. Neither proteinuria, sex nor the causative gene influences the presence of KC in these individuals. OrderedDict([(u'fig', OrderedDict([(u'@position', u'float'), (u'@id', u'ga1'), (u'label', u'Graphical Abstract'), (u'graphic', OrderedDict([(u'@xlink:href', u'gfae031fig1g'), (u'@position', u'float')]))]))]).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

How genomics reclassifies diseases, the case of Alport syndrome

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
In this issue, Matthews et al. provide a comprehensive review of published cohorts with heterozygous pathogenic variants in COL4A3 or COL4A4, documenting the wide spectrum of the disease. Due to the extreme phenotypes that patients with heterozygous pathogenic variants in COL4A3 or COL4A4 may show, the disease has been referred to in a variety of ways, including 'autosomal dominant Alport syndrome', 'thin basement membrane disease', 'thin basement membrane nephropathy', 'familial benign hematuria' and 'carriers of autosomal dominant Alport syndrome'. This confusion over terminology has prevented nephrologists from being sufficiently aware of the relevance of the entity. Nowadays, however, next-generation sequencing facilitates the diagnosis and it is becoming a relatively frequent finding in haematuric-proteinuric nephropathies of unknown origin, even in non-familial cases. There is a need to raise awareness among nephrologists about the disease in order to improve diagnosis and provide better management for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

  • Naranjo, Javier|||0000-0002-7004-6122
  • Furlano, Monica|||0000-0003-1025-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Pybus, Marc|||0000-0002-6195-5738
  • Ejarque, Laia
  • Cordoba, Christian|||0000-0003-4534-2760
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. Methods: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C-1E was assessed. Results: A total of 118 patients were MC 1C-1E. The algorithm developed by the European Renal Association-European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C-1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Genetic Features of Autosomal Dominant Alport Syndrome, A Cohort Study

  • Furlano, Monica|||0000-0003-1025-3901
  • Martínez, Victor
  • Pybus, Marc|||0000-0002-6195-5738
  • Arce, Yolanda
  • Crespí, Jaume|||0000-0001-7564-2479
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Domingo, Andrea|||0000-0003-3759-7595
  • Ayasreh Fierro, Nadia|||0000-0001-6436-5621
  • Benito, Silvia
  • Lorente, Laura
  • Ruíz, Patricia
  • Gonzalez, Vanesa L.
  • Arlandis, Rosa
  • Cabello, Elisa
  • Torres, Ferran|||0000-0002-7355-7913
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Rationale & Objective: Alport syndrome is a common genetic kidney disease accounting for approximately 2% of patients receiving kidney replacement therapy (KRT). It is caused by pathogenic variants in the gene COL4A3, COL4A4, or COL4A5. The aim of this study was to evaluate the clinical and genetic spectrum of patients with autosomal dominant Alport syndrome (ADAS). Study Design: Retrospective cohort study. Setting & Participants: 82 families (252 patients) with ADAS were studied. Clinical, genetic, laboratory, and pathology data were collected. Observations: A pathogenic DNA variant in COL4A3 was identified in 107 patients (35 families), whereas 133 harbored a pathogenic variant in COL4A4 (43 families). Digenic/complex inheritance was observed in 12 patients. Overall, the median kidney survival was 67 (95% CI, 58-73) years, without significant differences across sex (P = 0.8), causative genes (P = 0.6), or type of variant (P = 0.9). Microhematuria was the most common kidney manifestation (92.1%), and extrarenal features were rare. Findings on kidney biopsies ranged from normal to focal segmental glomerulosclerosis. The slope of estimated glomerular filtration rate change was -1.46 (-1.66 to -1.26) mL/min/1.73 m per year for the overall group, with no significant differences between ADAS genes (P = 0.2). Limitations: The relatively small size of this series from a single country, potentially limiting generalizability. Conclusions: Patients with ADAS have a wide spectrum of clinical presentations, ranging from asymptomatic to kidney failure, a pattern not clearly related to the causative gene or type of variant. The diversity of ADAS phenotypes contributes to its underdiagnosis in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease

  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
  • Matamala Gastón, Ana María
  • Brossa Loidi, Vicens|||0000-0003-0403-6425
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Crespí, Jaume|||0000-0001-7564-2479
  • Roé Crespo, Esther|||0000-0003-1601-9227
  • Torra Balcells, Roser|||0000-0001-8714-2332
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants of the GLA gene. Heterozygous female patients may show much more variability in clinical manifestations, ranging from asymptomatic to full-blown disease. Because of this heterogeneous clinical picture in women, the diagnosis of FD has typically been delayed for more than a decade, and the optimal time to initiate treatment remains controversial. Case Presentation. Here, we present two unrelated female patients diagnosed with FD harbouring the same pathogenic GLA variant. We discuss the implications of initiating specific therapy at different stages of the disease, with and without organ involvement (early versus late therapeutic intervention). These clinical cases suggest that initiating specific treatment at an earlier age in women with FD may prevent organ involvement and associated clinical events.